CONTRIBUTION OF THE HYPOXIA-ODZ1 AXIS TO THE INVASIVE CAPACITY OF GLIOBLASTOMA (Q3138921): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Created claim: summary (P836): The low survival of glioblastoma (GBM) patients has been attributed to their genetic heterogeneity and tumor microenvironment factors such as hypoxia and aberrant signs of growth factors. One of the most prominent features of the GBM is its high infiltrating capacity, which adds great complexity to the clinical management of patients. Recently, we described that the transmembranal protein ODZ1, induces an invasive mesenchymal phenotype in GBM ce...)
(‎Changed label, description and/or aliases in en: translated_label)
label / enlabel / en
 
CONTRIBUTION OF THE HYPOXIA-ODZ1 AXIS TO THE INVASIVE CAPACITY OF GLIOBLASTOMA

Revision as of 13:20, 12 October 2021

Project Q3138921 in Spain
Language Label Description Also known as
English
CONTRIBUTION OF THE HYPOXIA-ODZ1 AXIS TO THE INVASIVE CAPACITY OF GLIOBLASTOMA
Project Q3138921 in Spain

    Statements

    0 references
    36,000.0 Euro
    0 references
    72,000.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2018
    0 references
    31 March 2021
    0 references
    FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (IDIVAL)
    0 references
    0 references

    43°27'43.34"N, 3°48'35.89"W
    0 references
    39075
    0 references
    La baja supervivencia de los pacientes con glioblastoma (GBM) se ha atribuido a su heterogeneidad genética y a factores del microambiente tumoral tales como la hipoxia y las señales aberrantes de factores de crecimiento. Una de las características más destacadas del GBM es su elevada capacidad infiltrante, que añade una gran complejidad al manejo clínico de los pacientes. Recientemente, describimos que la proteína transmembranal ODZ1, induce un fenotipo mesenquimal invasivo en las células de GBM activando la ruta transcripcional Myc-RhoA. Por otro lado, la hipoxia es clave en la invasión tumoral y se asocia a la activación de Myc, entre otros factores, y al fenotipo mesenquimal en GBM. Pese a su relevancia, no se conocen marcadores específicos de hipoxia. Cabe añadir que la hipoxia promueve cambios epigenéticos por metilación del DNA y que nuestros datos preliminares relacionan la expresión de ODZ1 con procesos de isquemia/hipoxia cerebral. En base a esto, nos proponemos estudiar la contribución de ODZ1 en el proceso invasivo del GBM y su relación con la hipoxia. Para ello utilizaremos modelos in vitro e in vivo de GBM y analizaremos imágenes de RMN y biopsias de pacientes. Pretendemos, en definitiva, aportar evidencias sobre el valor pronóstico de ODZ1 y de un posible marcador específico de hipoxia (firma epigenética) en GBM y determinar si ODZ1 es un mediador del efecto invasivo de la hipoxia. (Spanish)
    0 references
    The low survival of glioblastoma (GBM) patients has been attributed to their genetic heterogeneity and tumor microenvironment factors such as hypoxia and aberrant signs of growth factors. One of the most prominent features of the GBM is its high infiltrating capacity, which adds great complexity to the clinical management of patients. Recently, we described that the transmembranal protein ODZ1, induces an invasive mesenchymal phenotype in GBM cells by activating the Myc-RhoA transcriptional pathway. On the other hand, hypoxia is key in tumor invasion and is associated with the activation of Myc, among other factors, and the mesenchymal phenotype in GBM. Despite their relevance, no specific markers of hypoxia are known. It should be added that hypoxia promotes epigenetic changes by DNA methylation and that our preliminary data relate the expression of ODZ1 to processes of cerebral ischemia/hypoxia. Based on this, we intend to study the contribution of ODZ1 to the invasive process of the BBM and its relationship with hypoxia. For this we will use in vitro and in vivo models of GBM and analyse images of MRI and biopsies of patients. In short, we intend to provide evidence on the prognostic value of ODZ1 and a possible specific marker of hypoxia (epigenetic signature) in GBM and to determine whether ODZ1 is a mediator of the invasive effect of hypoxia. (English)
    12 October 2021
    0 references
    Santander
    0 references

    Identifiers

    PI17_01399
    0 references